Prestige Consumer Healthcare stock in January (2026)

Prestige Consumer He...

NYSE:PBH

$ 61,22

$0,00 (0,00%)

61,22 $

$0,00 (0,00%)

End-of-day quote: 01/05/2026

Prestige Consumer Healthcare Stock Value

Analysts currently rate NYSE:PBH as Outperform.

Outperform

Prestige Consumer Healthcare Company Info

EPS Growth 5Y

8,84%

Market Cap

$2,94 B

Long-Term Debt

$0,99 B

Short Interest

3,72%

Quarterly earnings

02/06/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1996

Industry

Consumer Staples

Country

United States

ISIN Number

US74112D1019

Website

http://www.prestigebrands.com

Analyst Price Target

$78,50

28.23%

Last Update: 01/06/2026

Analysts: 6

Highest Price Target $88,00

Average Price Target $78,50

Lowest Price Target $70,00

In the last five quarters, Prestige Consumer Healthcare’s Price Target has fallen from $71,65 to $71,50 - a -0,21% decrease. Eight analysts predict that Prestige Consumer Healthcare’s share price will increase in the coming year, reaching $78,50. This would represent an increase of 28,23%.

Top growth stocks in the consumer staples sector (5Y.)

What does Prestige Consumer Healthcare do?

Prestige Consumer Healthcare Inc. (‘Prestige’) engages in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (‘OTC’) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. The company uses the strength of its brands and its established retail distribution ne...

The company uses the strength of its brands and its established retail distribution network. The company has grown its product portfolio both organically and through acquisitions. It develops its existing brands by investing in new product lines, brand extensions, and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of its growth strategy. The company pursues this growth following an acquisition through spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.

Segments

The company conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare.

North American OTC Healthcare

BC and Goody's: The BC and Goody's brands feature over-the-counter, fast-acting pain relief powder.

Boudreaux's Butt Paste: Products include various diaper rash treatments and skin protectants manufactured with high-quality ingredients.

Chloraseptic: Products include sprays and lozenges to relieve sore throats and mouth pain.

Clear Eyes: An effective line of eye care products that provide soothing comfort, including relief from redness and itchiness.

Compound W: Provides safe and effective at-home removal of common and plantar warts.

Debrox: Provides a safe and gentle way to remove excess ear wax or water from the ear canal.

DenTek: Products include dental guards, floss picks, interdental brushes, dental repair kits, and tongue cleaners.

Dramamine: Includes non-drowsy, kids', original, and nausea-free formulas.

Fleet: Products include enemas and other laxative products.

Gaviscon: Creates a protective foam barrier to help block stomach acid from splashing up into the esophagus.

Luden's: A cough drop brand that is over 130 years old and includes a variety of flavors.

Monistat: Provides fast relief for yeast infections and is available in several different doses.

Nix: Effective and safe lice and super lice treatments.

Summer's Eve: Offers a variety of feminine care products, including washes, cloths, and sprays.

TheraTears: A doctor-created and recommended brand for dry eye relief.

International OTC Healthcare

Fess: Helps relieve nasal and sinus congestion due to allergy, hay fever, colds, and flu.

Hydralyte: Relieves symptoms of dehydration and helps replace water and electrolytes lost due to vomiting, diarrhea, heavy sweating, vigorous exercise, and occasional hangovers.

The company’s products are sold through multiple channels, including mass merchandisers, drug, food, dollar, convenience, club, and e-commerce stores, which reduces its exposure to any single distribution channel.

Growth Strategy

The company’s strategies include a diversified portfolio of well-recognized and established consumer brands, strong competitive positioning in attractive categories, proven ability to develop and introduce new products, investments in advertising and marketing, increasing distribution across multiple channels, pursuing strategic acquisitions, growing the company’s international business, and proven ability to acquire, integrate, and grow brands.

Marketing and Sales

The company’s marketing strategy is further developed by the acquisition and renovation of established consumer brands.

Customers

The company’s senior management team and dedicated sales force strive to maintain long-standing relationships with its top customers. The company also contracts with third-party sales management enterprises that interface directly with many of its remaining customers and report directly to members of its sales management team. In an effort to ensure continued sales growth, the company continues to focus on expanding its reliance on direct sales while reducing its reliance on brokers.

The company enjoys broad distribution across each of the major retail channels, including mass merchandisers, drug, food, dollar, convenience, club stores, and e-commerce channels. During 2025, Walmart accounted for approximately 19% of the company’s gross revenue. During 2025, Amazon accounted for approximately 14% of its gross revenue.

Competition

The company’s branded competitors include, among others, AbbVie Inc., Alcon, Bausch + Lomb, Bayer AG, Combe, Compass Diversified, Haleon plc, Kenvue, Mondelez International, Reckitt Benckiser Group plc, Sanofi, Scholl's Wellness Company, Sunstar Group, The Procter & Gamble Company, and Unilever.

Regulation

The formulation, manufacturing, packaging, labeling, distribution, importation, sale, and storage of the company’s products are subject to extensive regulation by various U.S. federal agencies, including the U.S. Food and Drug Administration (‘FDA’), the Federal Trade Commission (‘FTC’), the Consumer Product Safety Commission (‘CPSC’), and the Environmental Protection Agency (‘EPA’), as well as various agencies of the states, localities, and foreign countries in which the company’s products are manufactured, marketed, distributed, and sold.

Most of the company’s U.S. OTC drug products are regulated pursuant to the FDA’s monograph system, initially established in 1972. The monograph system establishes conditions, such as active ingredients, uses or indications, doses, routes of administration, labeling, and testing, under which certain broad categories of the U.S. OTC drug products are generally recognized as safe and effective for their intended use.

Certain of the company’s U.S. OTC drug products require the submission of a New Drug Application (‘NDA’) or Abbreviated New Drug Application (‘ANDA’). These specific OTC drug products cannot be marketed until the FDA approves the NDA or ANDA, and after approval, are manufactured and labeled in accordance with an FDA-approved submission.

Certain of the company’s U.S. OTC Healthcare products are medical devices regulated by the FDA through one of three classes of medical devices: Class I devices are low-risk devices, Class II devices are intermediate-risk devices, and Class III devices are high-risk devices.

Certain of the company’s products are considered cosmetics regulated by the FDA through the FDC Act and the Fair Packaging and Labeling Act.

In accordance with the Federal Food, Drug, and Cosmetic Act (‘FDC Act’) and FDA regulations, the company and its third-party manufacturers of the U.S. products must also comply with the FDA’s current Good Manufacturing Practices (‘cGMPs’). The FDA inspects the company’s facilities and those of its third-party manufacturers periodically to determine that both the company and its third-party manufacturers are complying with cGMPs.

The company’s dietary supplement products are governed by the Dietary Supplement Health and Education Act of 1994 (‘DSHEA’), which defines and regulates dietary supplements. Under DSHEA, the FDA published a final rule that requires persons who manufacture, package, label, or hold a dietary supplement to establish and follow cGMPs.

A number of the company’s products are also regulated by the Consumer Product Safety Commission (‘CPSC’) under the Federal Hazardous Substances Act (‘FHSA’), the Poison Prevention Packaging Act of 1970 (the ‘PPPA’), and the Consumer Products Safety Improvement Act of 2008 (‘CPSIA’). The CPSIA requires the company to make available to its customers certificates stating that it is in compliance with any applicable regulation administered by the CPSC.

The company is subject to the Federal Trade Commission (‘FTC’) and state regulations, as well as foreign regulations, relating to its product claims and advertising.

Intellectual Property

The company owns a number of trademark registrations and applications in the United States, Canada, and other foreign countries. The following are some of the most significant registered trademarks owned by the company in the United States and/or Canada: BC, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Goody's, Luden's, Monistat, Nix, Summer's Eve, and TheraTears. While the company’s trademarks and trade names generally have indefinite lives if well maintained, its patents have defined lives expiring between 2025 and 2046.

History

The company was founded in 1996 as a joint venture of Medtech Labs and The Shansby Group. It was incorporated in the state of Delaware in 2004. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in 2018.

Prestige Consumer Healthcare Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Industry Revenues: OTC Pharmaceuticals: approx. 70% Health and Wellness Products: approx. 20% Personal Care Products: approx. 10% TOP 3 Markets: USA: approx. 75% Canada: approx. 10% Europe: approx. 8% Prestige Consumer Healthcare Inc. generates the majority of its revenues from the OTC Pharmaceu...

At which locations are the company’s products manufactured?

Production Sites: USA, Canada Prestige Consumer Healthcare Inc. produces the majority of its products in the United States and Canada. The company places great emphasis on the quality and safety of its products, which is why it focuses on North American production sites. This not only allows for bet...

What strategy does Prestige Consumer Healthcare pursue for future growth?

Revenue Growth: 4.8% (2025) Profit Growth: 6.2% (2025) Prestige Consumer Healthcare Inc. pursues a growth strategy that heavily focuses on expanding its product portfolio and geographic expansion. The company continuously invests in developing new healthcare products to meet changing consumer needs...

Which raw materials are imported and from which countries?

Main raw materials: Pharmaceutical active ingredients, packaging materials Countries of origin: China, India, USA Prestige Consumer Healthcare Inc. mainly imports pharmaceutical active ingredients and packaging materials needed for the production of their health products. The pharmaceutical active i...

How strong is the company’s competitive advantage?

Market Share: 5.2% in the OTC healthcare market (2025, estimated) EBITDA Margin: 28.4% (2025) R&D Expenses: 2.1% of revenue (2025) Prestige Consumer Healthcare Inc. has a solid competitive advantage in the over-the-counter (OTC) healthcare products market. The company benefits from strong brand...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: approximately 95% (estimated for 2026 based on historical data) Insider Buys/Sells: No significant transactions in the last year (estimated) Prestige Consumer Healthcare Inc. has traditionally had a high institutional investor share, indicating the trust of large invest...

What percentage market share does Prestige Consumer Healthcare have?

Market share of Prestige Consumer Healthcare Inc.: Estimated 3-5% (2026) Top competitors and their market shares: Johnson & Johnson (NYSE:JNJ): approx. 15-20% Procter & Gamble Co. (NYSE:PG): approx. 10-15% Bayer AG (ETR:BAYN): approx. 8-12% GlaxoSmithKline plc (LSE:GSK): approx. 5-10% Recki...

Is Prestige Consumer Healthcare stock currently a good investment?

Revenue Growth: 6.5% (2025) Profit Growth: 5.2% (2025) Market Share in the Healthcare Sector: 3.8% (2025) Prestige Consumer Healthcare Inc. recorded a solid revenue growth of 6.5% in 2025, attributed to strong demand for their healthcare products and an effective distribution strategy. The profit gr...

Does Prestige Consumer Healthcare pay a dividend – and how reliable is the payout?

Dividend payment: No (as of 2026) Prestige Consumer Healthcare Inc. currently does not pay a dividend. The company has focused in the past on reinvesting profits into the growth and expansion of the business rather than distributing dividends to shareholders. The reliability of the payout is therefo...

New support ticket

Prestige Consumer Healthcare Stock Value

Prestige Consumer Healthcare Company Info

Analyst Price Target

Top growth stocks in the consumer staples sector (5Y.)

What does Prestige Consumer Healthcare do?

Prestige Consumer Healthcare Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal